BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Agilent and Incyte Team Up for Advanced Diagnostics in Hematology & Oncology

The value of the companion diagnostics market is predicted to expand to nearly US $14B by 2030, driven in part by the power of these tests to inform t...

February 01, 2024 | News

CellVax Therapeutics Receives FDA Clearance for FK-PC101 Cancer Immunotherapy IND

FK-PC101 is CellVax's novel personalized cancer immunotherapy intended to treat prostate cancer patients who have a high risk of recurrence after prostatec...

January 30, 2024 | News

FDA Designates Amadix's Blood Test as Breakthrough Device for Colorectal Cancer Screening

PreveCol®, a blood test for oncological diagnosis, has obtained US recognition for its efficacy in detecting precancerous lesions compared to existin...

January 24, 2024 | Regulatory

AIM ImmunoTech Initiates Phase 1b/2 Trial for Ampligen® and AstraZeneca's Imfinzi® in Late-Stage Pancreatic Cancer

AIM ImmunoTech Inc. announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM&rs...

January 23, 2024 | News

Merck's JAVELIN Bladder Regimen Shines in Real-World Data, Elevating Standard Care for Urothelial Carcinoma

Merck, a distinguished science and technology company, has announced groundbreaking real-world data that further solidify the JAVELIN Bladder regimen as a ...

January 23, 2024 | News

AstraZeneca's IMFINZI Combo Shows Significantly Improved Survival in Liver Cancer

Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demo...

January 22, 2024 | News

BostonGene and Prisma Health Collaborate to Predict Immunotherapy Efficacy in Rare Cancers

BostonGene, a leading provider of AI-based molecular and immune profiling solutions provider, today announces a collaboration with Prisma Health aimed at a...

January 19, 2024 | News

Qure.ai and Project Data Sphere Merge Big Pharma Insights with Deep AI for Advancing Cancer Care

In a pivotal stride toward advancing cancer care, Qure.ai, a leader in artificial intelligence (AI) solutions for medical imaging, and Project Data Sp...

January 19, 2024 | News

CMS Grants Favorable Reimbursement for RefleXion’s SCINTIX Therapy

The CMS has established a national payment rate for RefleXion's SCINTIX® biology-guided radiotherapy using CMS' New Technology Ambulatory Payment Class...

January 16, 2024 | News

CARsgen's CT011 Granted NMPA IND Clearance for GPC3-Positive Stage Ⅲa Liver Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

January 16, 2024 | News

Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

First-in-class ompenaclid (RGX-202) currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer Collaboration includes ex...

January 09, 2024 | News

Guardant Health, Hikma Partner for Cancer Testing in the Middle East and North Africa

The partnership expands Guardant Health's global presence and includes products across the cancer care continuum. The tests offered include Shield™ f...

January 09, 2024 | News

Menarini Group and Insilico Medicine Ink Exclusive Deal for Novel KAT6 Inhibitor in Oncology, Including Breast Cancer Treatment

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in...

January 05, 2024 | News

Merck Broadens Colorectal Cancer Portfolio via Licensing Deal with Inspirna

First-in-class ompenaclid (RGX-202) currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer Collaboration includes ex...

January 05, 2024 | News

Stay Connected